Mercy BioAnalytics Appoints Dawn Mattoon, PhD, as Chief Operating Officer

Rhea-AI Summary

Mercy BioAnalytics has appointed Dr. Dawn Mattoon as Chief Operating Officer, effective immediately. With a 20-year career in biotechnology, Dr. Mattoon previously led Clinical Diagnostics at Quanterix Corporation, overseeing the launch of COVID-19 tests and securing FDA Breakthrough Device designations for Alzheimer's and Multiple Sclerosis diagnostics. Her expertise will bolster Mercy's efforts in commercializing the Mercy Halo™ early cancer detection platform, which targets hard-to-detect ovarian and lung cancers. CEO Paul Blavin expressed optimism for growth under her leadership.

Positive

• Appointment of Dr. Dawn Mattoon as COO brings extensive experience from Quanterix Corporation and Thermo Fisher Scientific.
• Dr. Mattoon's background in leading FDA-authorized diagnostic tests may enhance Mercy's credibility and operational efficiency.
• Focus on the early detection of ovarian and lung cancers aligns with high unmet medical needs, potentially increasing market opportunities.

Negative

• Concerns about continuity in company leadership during a pivotal growth phase with commercial launch plans.
• Potential experience gaps in specific areas of biotechnology and operational management at Mercy BioAnalytics.

NATICK, Mass.--(BUSINESS WIRE)-- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of experienced biotechnology executive, Dawn Mattoon, PhD, as Chief Operating Officer, effective today. In her nearly 20-year career, Dr. Mattoon has developed and commercialized a broad range of innovative proteomic and genomic technologies.

Dr. Mattoon possesses a proven track record of delivering top and bottom-line growth as a leader in research and development, strategy, and general management for companies such as Invitrogen, Life Technologies, Thermo Fisher Scientific Inc. (NYSE: TMO), and Cell Signaling Technologies. Most recently, Dr. Mattoon served as Senior Vice President of Clinical Diagnostics at Quanterix Corporation (Nasdaq: QTRX), where she led the development and commercialization of the company’s first FDA-authorized diagnostic tests for COVID-19 and received FDA Breakthrough Device designations for diagnostic tests addressing Alzheimer’s Disease and Multiple Sclerosis. She holds a PhD in molecular genetics from Yale University, where she also completed her postdoctoral fellowship.

“We are humbled to welcome Dr. Mattoon to the Mercy family at an important moment in our drive towards global commercialization of our powerful Mercy Halo™ early cancer detection test platform. The clinical studies of our technology in ovarian and lung cancer presented recently at the American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) conferences provide promising evidence of the diagnostic potential of this approach, and we are excited that Dr. Mattoon shares our passion for our mission to relieve suffering and save lives through the early detection of cancer,” said Mercy BioAnalytics CEO Paul Blavin. “We look forward to benefitting from her experience as she assumes her role overseeing Mercy’s expanding business footprint, including scientific, clinical, and commercial operations.”

“Mercy is bringing a highly differentiated approach to the early detection of cancer and has assembled a world-class network of colleagues, collaborators, and partners to deliver on the vision of improving the lives of cancer patients and their families,” said Dr. Mattoon. “I have a passion for building businesses based on impactful, innovative clinical products, and am thrilled to be part of a company with such tremendous potential to benefit the global community.”

Read a recent profile on Mercy BioAnalytics published by GenomeWeb here.

ABOUT MERCY BIOANALYTICS

Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo™ platform is designed to detect stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate, and colorectal cancers combined. For additional information, please visit https://www.mercybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005164/en/

Michelle McAdam, Chronic Communications Inc.

michelle@chronic-comm.com

310.902.1274

Source: Mercy BioAnalytics, Inc.

FAQ

What recent management change was announced by Mercy BioAnalytics?

Mercy BioAnalytics announced the appointment of Dr. Dawn Mattoon as Chief Operating Officer, effective immediately.

What is Dr. Dawn Mattoon's background relevant to her new role at Mercy BioAnalytics?

Dr. Mattoon has nearly 20 years of experience in biotechnology, previously serving at Quanterix Corporation and Thermo Fisher Scientific, and has led FDA-authorized diagnostics.

How might Dr. Mattoon's appointment impact Mercy BioAnalytics's business?

Her expertise could enhance the commercialization efforts of Mercy's cancer detection platform and improve operational efficiency.